FDA hits Simtra BioPharma Solutions with warning letter over German site
The agency cited the CDMO’s significant violations of current Good Manufacturing Practice regulations for finished pharmaceuticals at Simtra’s Halle/Westfalen facility.
Read the full article on the original site.
Read Full Article